NEJM This Week (2026-08-20): Mucoregulators in Acute Respiratory Failure, Childhood Wheeze, First-line EGFR ex20ins NSCLC, and Myeloproliferative Neoplasms

Acute respiratory failure: RCT in 1,956 mechanically ventilated patients with acute respiratory failure; adding carbocisteine (mucoregulator) or nebulized hypertonic saline to usual care showed no benefit and possible harm, suggesting caution and re-evaluation of mucoactive agents in the clinic. Pediatric wheeze: RCT in 840 children aged 18–59 months with moderate-to-severe wheeze (azithromycin for 5 days vs placebo), stopped early for futility by the data safety monitoring board; the subgroup (positive nasopharyngeal culture) also showed no benefit, possibly because concurrent eosinophilic inflammation was masked by corticosteroids. Lung cancer: phase 3 first-line trial of sunvozertinib (already granted accelerated approval for post-chemotherapy EGFR ex20ins advanced NSCLC) in 324 patients, adding first-line efficacy and safety data. Hematology: review of classical myeloproliferative neoplasms (ET/PV/PMF)—driven by acquired gain-of-function mutations in JAK2/CALR/MPL, with mutations preceding clinical disease by decades; inflammation promotes clonal dominance and progression to myelofibrosis/thrombosis/secondary AML; treatment is mainly symptom control, with peg-IFNα and JAK2 inhibitors offering some disease-modifying effect. Perspective: LLM-driven "AI copilots" can draft medical records and generate differential diagnoses, but overreliance may lead to degradation of clinical skills; other Perspectives include medical cannabis research and sexual/gender minority health (AI is only one perspective topic in this issue, not the main focus of this video, and is not tagged AI4Science).

• Acute respiratory failure: RCT in 1,956 mechanically ventilated patients with acute respiratory failure; adding carbocisteine (mucoregulator) or nebulized hypertonic saline to usual care showed no benefit and possible harm, suggesting caution and re-evaluation of mucoactive agents in the clinic.
• Pediatric wheeze: RCT in 840 children aged 18–59 months with moderate-to-severe wheeze (azithromycin for 5 days vs placebo), stopped early for futility by the data safety monitoring board; the subgroup (positive nasopharyngeal culture) also showed no benefit, possibly because concurrent eosinophilic inflammation was masked by corticosteroids.
• Lung cancer: phase 3 first-line trial of sunvozertinib (already granted accelerated approval for post-chemotherapy EGFR ex20ins advanced NSCLC) in 324 patients, adding first-line efficacy and safety data.
• Hematology: review of classical myeloproliferative neoplasms (ET/PV/PMF)—driven by acquired gain-of-function mutations in JAK2/CALR/MPL, with mutations preceding clinical disease by decades; inflammation promotes clonal dominance and progression to myelofibrosis/thrombosis/secondary AML; treatment is mainly symptom control, with peg-IFNα and JAK2 inhibitors offering some disease-modifying effect.
• Perspective: LLM-driven "AI copilots" can draft medical records and generate differential diagnoses, but overreliance may lead to degradation of clinical skills; other Perspectives include medical cannabis research and sexual/gender minority health (AI is only one perspective topic in this issue, not the main focus of this video, and is not tagged AI4Science).